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In this issue, Fribourg et al. provide insight into a molecular basis of psychosis. They reveal that
a heteromeric complex formed by the G protein-coupled receptors (GPCRs) for glutamate and
serotonin is a convergent site for the activity of anti- or propsychotic drugs, opening a possibility
for new therapeutic strategies for schizophrenia.Psychosis is a brain condition that
includes hallucinations, delusions, and
disorganization of semantic content of
speech and writing due, in part, to distur-
bances in perception and other higher
brain functions. This is also described as
loss of contact with reality. Psychosis
occurs in many brain conditions with
distinct etiologies, such as substance
abuse and brain injury, and it is well-
known as a key manifestation of schizo-
phrenia, a devastating chronic mental
illness that affects about 1% of the global
population. In this issue of Cell, a study
reveals that a heteromeric complex
formed between the metabotropic gluta-
mate 2 receptor (mGluR2) and the sero-
tonin 5-HT2A receptor (2AR) integrates
the actions of drugs that exert positive
and negative influences on psychosis (Fri-
bourg et al., 2011). 2AR is a Gq-coupled
GPCR that responds to serotonin,
whereas mGluR2 is a Gi-coupled GPCR
that responds to glutamate.
Following the serendipitous introduc-
tion of chlorpromazine for treatment of
psychotic patients in the early 1950s,
investigators studied the pharmacolog-
ical mechanism of chlorpromazine and
related compounds. They proposed that
the blockade of dopamine D2 receptors
(D2R) by these ‘‘classic or typical neuro-
leptics’’ predicts clinical and pharmaco-
logical potencies (Creese et al., 1976).
More recently, clozapine and a group of
compounds called ‘‘atypical or second-
generation neuroleptics’’ have emerged.
These compounds are generally more
effective for treating psychosis than the
classic neuroleptics. In addition, these
atypical neuroleptics show high affinity964 Cell 147, November 23, 2011 ª2011 Elsefor the 2AR over the D2R. Although
many psychedelic drugs, including LSD,
also target 2AR, some compounds with
high affinity for 2AR do not influence
psychotic manifestations, indicating that
the precise role of 2AR in psychosis is
yet to be elucidated. In the past decade,
another class of drugs, the mGluR2/3
agonists, have gained attention for their
amelioration of schizophrenia-like behav-
iors elicited by phencyclidine in rodents
(Moghaddam and Adams, 1998). In
some clinical trials, these same com-
pounds have shown some therapeutic
effects on patients with schizophrenia
(Patil et al., 2007).
A previous report illustrated that the
2AR and mGluR2 receptors physically
interact in pyramidal neurons of the
somatosensory cortex (Gonza´lez-Maeso
et al., 2008). In this issue of Cell, Fribourg
et al. investigate the intracellular signaling
properties of the mGluR2/2AR hetero-
complex in Xenopus oocytes and show
that the heteromeric assembly of 2AR
and mGluR2 enhances Gi signaling and
reduces Gq signaling. The authors intro-
duce a metric called the balance index
(BI), which describes the balance of Gi
and Gq signaling, and demonstrate that
ligand binding to both mGluR2 and 2AR
alters the BI (Figure 1). Most importantly,
the investigators observe that the BI
can predict the anti- or propsychotic
activities of drugs targeting mGluR2 and
2AR. Drugs with the most effective
antipsychotic properties, regardless of
which receptor they target, have high BI
values, whereas drugs with the most
effective propsychotic properties have
low BI values. With a rodent model ofvier Inc.psychotic-like behaviors elicited by
MK801, a noncompetitive antagonist of
the NMDA-type glutamate receptor, the
authors demonstrate that both 2AR and
mGluR2 are required for the antipsychotic
action.
This intriguing work sets the foundation
for future work and raises important
questions. This study uses knockout
mice to elegantly illustrate the interde-
pendency of mGluR2 and 2AR for bind-
ing drugs. However, it is still unclear in
which specific cells these two GPCRs
form the heteromeric assembly within
the brain. Cell type- and/or region-
specific knockout mice may be useful to
further address this question.
Building on the demonstration that
clozapine (targeting 2AR) and LY37 (tar-
geting mGluR2) promote antipsychotic-
like behavior by targeting this heteromeric
complex, an important follow-up question
is whether other atypical neuroleptics
(e.g., olanzapine and risperidone) and
other drugs that target mGluR2 elicit
the same effects on psychosis-relevant
behavioral changes as predicted by the
BI. This question is important when we
consider the historic studies by Snyder,
Seeman, and others that demonstrated
the actions of nearly 30 different classic
neuroleptics via D2R. They showed that
the relative affinity of these D2R antago-
nists strongly correlated with therapeutic
potency. Moreover, all of these drugs
were specific for the D2R, while lacking
correlation with histamine, serotonin, and
other receptors (Creese et al., 1976).
To further test the predictions of the BI,
the application of a recently described
assay for testing impaired detection of
Figure 1. Comparison between Classic
Neuroleptics and Newer Classes of Anti-
psychotics
Clinical potency of classic neuroleptics has been
understood on the basis of affinity to the dopamine
D2 receptor (D2R) (upper panel). In contrast, Fri-
bourg et al. propose that the intracellular Gi and Gq
signaling balance (BI), downstream of a hetero-
meric complex composed of the serotonin 5-HT2A
receptor (2AR) and metabotropic glutamate 2
receptor (mGluR2), provides a potential newmetric
for predicting the anti- or propsychotic activity of
drugs targeting 2AR and mGluR2 (lower panel).reality in rodents (McDannald et al., 2011)
will provide another, perhaps more rele-
vant, behavioral readout.
Fribourg and colleagues propose
a combined medication regime of gluta-mate antipsychotics and atypical neuro-
leptics (e.g., clozapine) at suboptimal
doses. Such treatments may result in
sufficient efficacy due to a synergistic
action via the mGluR2/2AR heterocom-
plex and could minimize the side effects
that come from normal doses of these
compounds, especially the metabolic
problems elicited by atypical neurolep-
tics. To consider this idea in a clinical
sense, we must pay careful attention to
the fact that these two classes of
compounds may also have independent
pharmacological actions from those regu-
lated by the mGluR2/2AR complex.
Convergence of cellular cascades down-
stream of receptors for dopamine, gluta-
mate, and serotonin was also explored
in the study of phosphodiesterases
(PDEs) in the context of molecular under-
standing and drug discovery for schizo-
phrenia (Menniti et al., 2006).
Many conditions accompanying psy-
chosis, especially schizophrenia, occur
after puberty or in young adulthood, and
therefore fundamental open questions
concern the neurodevelopmental trajec-
tory in these conditions. In particular, it
will be interesting to explore a potential
role for the mGluR2/2AR complex dur-
ing neurodevelopment, utilizing animal
models that manifest neurodevelopmen-
tal susceptibility with some relevance to
psychiatric illness (Brandon and Sawa,
2011).
Recently, schizophrenia research has
focused on cognitive deficits, which can
predict long-term disability. Nonetheless,
in real clinical settings, psychosis is still
amajor problemwith a substantial fraction
of patients showing resistance to all reper-
toires of neuroleptics currently available.
Thus, the proposal of this new potentialCell 147, Nmetric (the BI), which might be used in
drug screening for psychosis, is timely
and significant in offering a new way to
think about treatments. Going forward, it
should be important to validate the BI
with a combination of pharmacology,
genetics, molecular neurobiology, and
brain imaging (e.g., Sawa and Snyder,
2002). Moreover, the findings of Fribourg
and colleagues go beyond the scope of
neuropsychopharmacology and clinical
psychiatry, impinging on the biology of
cell signaling and demonstrating the
significance of GPCR heteromerization in
cellular and behavioral responses.
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